Showing 2251-2260 of 9355 results for "".
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://practicaldermatology.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Skin Cancer Champions to Host Inaugural Patient Advocacy Summithttps://practicaldermatology.com/news/skin-cancer-champions-to-host-inaugural-patient-advocacy-summit/2488209/Skin Cancer Champions will convene its inaugural Patient Advocacy Summit on October 30, 2026, in Boston, Massachusetts, bringing patients and caregivers together with clinicians and industry representatives to discuss nonmelanoma skin cancer care, emerging therapies, and patient advocacy.
- Review Explores Energy-based Devices in Gender-affirming Carehttps://practicaldermatology.com/news/review-explores-energy-based-devices-in-gender-affirming-care/2488181/Laser and energy-based devices (EBDs) may address several dermatologic concerns relevant to transgender patients, from unwanted hair and acne to postoperative scars and body contouring, according to a recent review by Zarghami et al. Laser Applications Span Hair Removal, Acne, and Postsur
- Picosecond Laser Study Links Immediate Whitening to Skin Tissue Responsehttps://practicaldermatology.com/news/picosecond-laser-study-links-immediate-whitening-to-skin-tissue-response/2488179/A new in vivo study offers a closer look at what immediate whitening (IW) may represent at the tissue level following picosecond laser irradiation. Researchers publishing in Lasers in Surgery and Medicine, the study evaluated the relationship among IW, vacuole formation, and melan
- Cherry Angiomas Linked to NF1-Related Vascular Changes: Studyhttps://practicaldermatology.com/news/cherry-angiomas-linked-to-nf1-related-vascular-changes-study/2488158/Cherry angiomas may be a previously underrecognized vascular manifestation of neurofibromatosis type 1 (NF1), according to findings from a prospective comparative study in JAMA Dermatology. Investigators evaluated 259 participants (102 individuals with confirmed NF1 and 157 contro
- Phase 3 Study Shows Sustained Psoriasis Responses With SSGJ-608https://practicaldermatology.com/news/phase-3-study-shows-sustained-psoriasis-responses-with-ssgj-608/2488143/A phase 3 trial of the investigational interleukin (IL)-17A–targeting monoclonal antibody (SSGJ-608) showed high response rates through 52 weeks among adults with moderate-to-severe plaque psoriasis. Investigators for the double-blind, placebo-controlled trial included 458 adults in the sa
- AbbVie Names 34 Immunology Scholarship Recipients for 2026https://practicaldermatology.com/news/abbvie-names-34-immunology-scholarship-recipients-for-2026/2488127/AbbVie has announced 34 recipients of its 2026 AbbVie Immunology Scholarship, according to a news release, marking the 10th year of a program designed to support students living with chronic inflammatory diseases as they pursue higher education. Since the scholarship launched in 2016, AbbV
- Three-Part Acne Scar Protocol Shows Progressive Changes Through 139 Dayshttps://practicaldermatology.com/news/three-part-acne-scar-protocol-shows-progressive-changes-through-139-days/2488104/A multimodal protocol combining subcision, injectable treatment, and fractional laser therapy was associated with reductions in facial atrophic acne scar dimensions in a prospective case series published in Biomedicines. Ultrasound Tracks Changes Through 139 Days The stud
- D-2570 Shows High PASI Response Rates in Phase 2 Psoriasis Studyhttps://practicaldermatology.com/news/d-2570-shows-high-pasi-response-rates-in-phase-2-psoriasis-study/2488078/A novel oral TYK2 inhibitor produced significantly higher skin clearance rates than placebo in patients with moderate-to-severe plaque psoriasis, according to research published in Journal of the American Academy of Dermatology. D-2570 is a TYK2 inhibitor under development for aut
- New Photoimmunotherapy Approach Targets T Cells and Tumor Antigenshttps://practicaldermatology.com/news/study-new-photoimmunotherapy-approach-targets-t-cells-and-tumor-antigens/2488067/A new activatable photoimmunotherapy platform may enable more selective depletion of pathogenic cells while limiting inflammatory effects associated with existing PIT approaches, according to new research. Photoimmunotherapy